RESP1000

RESP1000 is a preclinical-stage small molecule drug candidate being developed by the Swedish biotechnology company **Respiratorius**. It is designed as a novel bronchodilator for the treatment of chronic obstructive pulmonary disease (COPD) and severe asthma. The compound aims to achieve airway relaxation through a mechanism of action that is distinct from existing therapeutic classes, such as beta-2 adrenoceptor agonists and muscarinic antagonists. RESP1000 is specifically intended to address the small airways, which are a major site of airflow obstruction in severe respiratory diseases and are often inadequately treated by current standard-of-care medications.